3448 results for «2025年12月8日利尔化学002258基本面分析»

Filter By

3448 results

First guidelines for the treatment of LM disease issued by SOLACI and SIAC

22 May 2025 – From EuroPCR 2025

During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.

Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...

First guidelines for the treatment of LM disease issued by SOLACI and SIAC

One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases

20 May 2025 – From EuroPCR 2025

In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.

They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...

One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases

Learnings from LANDMARK and Compare-TAVI at 3 years

22 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.

LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...

Learnings from LANDMARK and Compare-TAVI at 3 years

Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice

21 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...

Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice

Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study

20 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).

The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...

Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study

Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques

21 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.

The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...

Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques

Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?

22 May 2025 – From EuroPCR 2025

How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...

Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?

Duration of DAPT in ACS: The DUAL-ACS Trial

31 Aug 2025

Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.

The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...

Author

Ali Nazmi Calik
David Newby

Author

David Newby
The DUAL-ACS Trial:

1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease

29 Oct 2025

Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco. 

Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights...

Guillaume Bonnet

Author

Guillaume BONNET

Author

Christian Spaulding
1-year SELUTION DeNovo results: DEB strategy vs. systematic DES in de novo coronary disease

Introducing our recognised EuroPCR Networkers!

Discover and follow the PCR Companions who have been invited to take a step further among the PCR Family -  sharing news of the Scientific Programme lined up in Paris on 20-23 May 2025, at the World-Leading Course in #interventionalcardiology.

PCR: Collaborative, inclusive and global

15 Nov 2025 – From PCR London Valves 2025

At PCR, collaboration and inclusion are at the heart of everything we do.

Together, we create an environment where expertise is shared, talents complement each other, and diversity becomes a strength. It is this collective spirit that drives interventional cardiology forward and inspires innovation every day.

During PCR London...

PCR: Collaborative, inclusive and global

Redo TAVI: how to treat different TAVI platforms when they fail?

22 May 2025 – From EuroPCR 2025

In this discussion, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.

Together, they address the main challenges faced in repeat procedures - chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...

Redo TAVI: how to treat different TAVI platforms when they fail?

TRIGISTRY: Advancing real-world understanding of tricuspid valve disease

07 Nov 2025

Edoardo Zancanaro interviews Julien Dreyfus and David Messika-Zeitoun about TRIGISTRY, an international registry that builds on the TRI-SCORE — now part of the 2025 ESC guidelines. The study confirms that early referral and optimal reduction of tricuspid regurgitation are key to improving outcomes. The team now...

TRIGISTRY insights

1-year SELUTION DeNovo results: what they mean for daily practice

29 Oct 2025

The SELUTION DeNovo trial, presented by Christian Spaulding at TCT 2025, delivers the first head-to-head comparison between a sirolimus DCB strategy and contemporary DES in PCI.

In this review, Salvatore Brugaletta breaks down the 1-year results and what these findings truly mean for everyday lesion-by-lesion decision-making.

Guillaume Bonnet

Author

Guillaume BONNET

Author

Christian Spaulding

Author

Salvatore Brugaletta
1-year SELUTION DeNovo results: what they mean for daily practice

How to manage coronary artery disease in TAVI candidates?

20 May 2025 – From EuroPCR 2025

Martine Gilard, Antonio Mangieri, and Marco Barbanti explore the strategy for handling coronary artery disease in patients undergoing TAVI. Is coronary angiography always required beforehand? Should PCI be performed in all cases—and if so, when? This exchange offers key insights to help guide your decisions on...

How to manage CAD in TAVI candidates?

What are the fundamentals of an upfront two-stent strategy for bifurcation PCI?

21 May 2025 – From EuroPCR 2025

Nicola Ryan explores the fundamentals of an upfront two-stent strategy in bifurcation PCI with Dejan Milasinovic. When the side branch shows significant, high-grade stenosis or extensive disease, direct treatment - via POBA, DCB, or a second stent - may be preferred. Anatomy guides the decision between...

What are the fundamentals of an upfront two-stent strategy for bifurcation PCI?

How to efficiently and safely manage calcified left main disease?

21 May 2025 – From EuroPCR 2025

Nicola Ryan and Flavio Ribichini explore the complexities of calcified left main stem disease, emphasizing the critical role of intracoronary imaging in improving patient outcomes. They discuss the practical use of mechanical circulatory support and debate stenting strategies, offering expert insights on when single or dual...

How to efficiently and safely manage calcified left main disease?

The D-PACE scoring system Prediction of high-grade conduction disturbances after TAVI

16 Nov 2025 – From PCR London Valves 2025

Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after TAVI—an unmet clinical need given that current risk models focus mainly on early events. The next steps aim to refine the...

The D-PACE scoring system - Can we predict high-grade conduction disturbances after TAVI?

Why is TAVI a different procedure in patient with pure aortic regurgitation?

15 Nov 2025 – From PCR London Valves 2025

In this video, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often underestimated. Early, comprehensive evaluation and imaging are crucial. Surgery is standard for severe cases, while TAVI with dedicated devices is an option for high-risk patients.

This...

Why is TAVI a different procedure in patient with pure aortic regurgitation?

What are the key considerations for transcatheter mitral paravalvular leak management?

18 Nov 2025 – From PCR London Valves 2025

Nina Wunderlich and Patrick Calvert discuss mitral paravalvular leaks, which are relatively common. Percutaneous closure is now the default approach, and imaging is central to success: detailed pre-procedural assessment, 3D TOE during the procedure, and careful planning of transseptal puncture. 

This interview was filmed at PCR London...

What are the key considerations for transcatheter mitral paravalvular leak management?
Didn’t find what you were looking for?